Please note, this OEL/ADE monograph also applies to lixisenatide acetate (CAS RN 1997361-87-1). Lixisenatide is a synthetic analogue of human glucagon-like peptide-1 (GLP-1) and a GLP-1 receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adult patients with type II diabetes mellitus (T2DM). As of 2026, lixisenatide is effectively no longer available as a standalone treatment in major global markets like the United States and the European Union for commercial reasons.
Affygility Solutions has an occupational exposure limit (OEL) and control band assignment for this active pharmaceutical ingredient (API). This monograph also contains the acceptable daily exposure (ADE) value.
OEL Fastrac monographs are a cost-effective and convenient way to meet the requirements for PDEs (ADEs) contained in the EMA Guideline on setting health based exposure limits for use in risk identification in the manufacture of different medicinal products in shared facilities (EMA/CHMP/CVMP/SWP/169430/2012), as well as PIC/S and ANVISA requirements, and to obtain the following information:
To order an OEL/ADE monograph for Lixisenatide, just click the ADD TO CART button.
If you're wondering about HBEL, we have something for you.
Not the compound you were looking for? You can search the OEL Fastrac catalog to find more available compounds.
Affygility Solutions’ OEL Fastrac service is an user-friendly system that enables us to make confident decisions and focus on moving the compound safely through our facility. We can quickly access the database to determine if a new drug is within the OEL Fastrac library, and if so, immediately download a detailed OEL banding report. The OEL Fastrac system has been a helpful tool in our overall EH&S program.